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this response. The rapid transactivation of
EGFR occurs by an intracellular Src-
mediated event, but not through the release
of an extracellular epidermal growth factor–
like ligand. These results suggest that the
early effects of COX-2– derived PGE2 are
in part mediated by EGFR, and this trans-
activation is responsible for subsequent
downstream effects, including the stimula-
tion of cell migration and invasion.5 In the
light of this information, we propose that
celecoxib may inhibit downstream signal-
ing of EGFR by decreasing the COX-2
protein and PGE2 levels, resulting in tumor
growth inhibition in NSCLC.
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Reply to the Editor:
We thank Ates and colleagues for their
thoughtful comments. We agree that there
is an interrelationship between the cyclo-
oxygenase-2 (COX-2) enzyme (and prosta-
noid products) and the epidermal growth
factor receptor (EGFR) family. In an im-
portant article, Pai and colleagues1 re-
ported that COX-2/prostaglandin E2 trans-
activates the EGFR receptor, with resultant
activation of downstream signaling.1 Sim-
ilarly it has been proposed that EGFR sig-
naling can increase COX-2 activity. These
findings have given cause for initiation of
human trials of combination therapy with
both EGFR receptor inhibitors and cele-
coxib in patients with non–small cell can-
cer, with some exciting initial results. How-
ever, the interaction between the two is
complex and as yet incompletely understood. 
Recently, Richardson and colleagues2 found
that COX-2 protein levels are independent of
EGFR expression or activation in patients
with non–small cell cancer.2 We have found
that combination therapy (EGFR receptor
blocker together with COX-2 blockade by
celecoxib) are occasionally antagonistic (at
least in one cell line) in an animal ortho-
topic lung cancer model. When under-
standing the interaction, though, it is im-
portant to realize that levels of the COX-2
enzyme (both messenger RNA and protein)
are variably affected by celecoxib, but the
activity of the enzyme is profoundly
blocked even by low doses of the drug.
With regard to final sentence of the letter,
we would agree that celecoxib decreases
PGE2 levels (but not COX-2 levels) and
that interactions with the EGFR cascade
probably account for some of the antineo-
plastic activity of the compound.
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